International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI)
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk (IPI) / Very Good (R-IPI)0–1
- Low-Intermediate Risk (IPI) / Good (R-IPI)2–2
- High-Intermediate Risk (IPI) / Poor (R-IPI)3–3
- High Risk (IPI) / Poor (R-IPI)4–5
The International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI) calculator is designed for bedside predicting overall and progression-free survival in diffuse large B-cell lymphoma (DLBCL) based on five independent risk factors in clinical practice. The resulting score directly guides clinician decision-making regarding.
Clinical Guidelines & Evidence
Predicts overall and progression-free survival in diffuse large B-cell lymphoma (DLBCL) based on five independent risk factors. The original IPI (International Prognostic Index) was developed in the pre-rituximab era and identifies four risk groups based on age, performance status, disease stage, LDH level, and extranodal involvement. The R-IPI (Revised IPI) was developed for the rituximab era to better discriminate outcomes in patients receiving R-CHOP therapy, redistributing patients into three prognostic groups with improved clinical utility. Both indices provide valuable prognostic information for treatment planning, clinical trial stratification, and patient counseling in DLBCL management.
Clinical Indication
The International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI) is indicated for bedside clinical practice to support Predicts overall and progression-free survival in diffuse large B-cell lymphoma (DLBCL) based on five independent risk factors. The original IPI (International Prognostic Index) was developed in the pre-rituximab era and identifies four risk groups based on age, performance status, disease stage, LDH level, and extranodal involvement. The R-IPI (Revised IPI) was developed for the rituximab era to better discriminate outcomes in patients receiving R-CHOP therapy, redistributing patients into three prognostic groups with improved clinical utility. Both indices provide valuable prognostic information for treatment planning, clinical trial stratification, and patient counseling in DLBCL management.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: The IPI remains useful for treatment planning and clinical trial stratification.
IPI Score = Age >60 (1) + LDH elevated (1) + Ann Arbor III/IV (1) + ECOG ≥2 (1) + >1 extranodal site (1). R-IPI redistributes into 3 groups: Very Good (0-1), Good (2), Poor (3-5)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age | string | Yes | Patient age at diagnosis(years) |
| ldh_level | string | Yes | Serum lactate dehydrogenase (LDH) level relative to upper limit of normal |
| ann_arbor_stage | string | Yes | Ann Arbor staging for lymphoma extent |
| ecog_performance_status | string | Yes | Eastern Cooperative Oncology Group (ECOG) performance status |
| extranodal_sites | string | Yes | Number of extranodal disease sites(sites) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–1 | Low Risk (IPI) / Very Good (R-IPI) | Score 0-1 points |
| 2–2 | Low-Intermediate Risk (IPI) / Good (R-IPI) | Score 2 points |
| 3–3 | High-Intermediate Risk (IPI) / Poor (R-IPI) | Score 3 points |
| 4–5 | High Risk (IPI) / Poor (R-IPI) | Score 4-5 points |
Evidence-Based References (EBM)
- A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993 Sep 30;329(14):987-94. doi: 10.1056/NEJM199309303291402.DOI: 10.1056/NEJM199309303291402
- The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007 Mar 1;109(5):1857-61. doi: 10.1182/blood-2006-08-038257.DOI: 10.1182/blood-2006-08-038257
- International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020 Jun 11;135(23):2041-2048. doi: 10.1182/blood.2019002729.DOI: 10.1182/blood.2019002729